Antitumor activity of the oncolytic peptide LTX-315 in syngeneic tumor models

被引：0
|
作者：
Camilio, Ketil Andre
Sveinbjornsson, Baldur
Maubant, Sylvie
Serin, Guillaume
Mirjolet, Jean-Francois
Bichat, Francis
Rekdal, Oystein
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-328
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
328
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma
    Xia, Yifeng
    Wei, Jingjing
    Zhao, Songsong
    Guo, Beibei
    Meng, Fenghua
    Klumperman, Bert
    Zhong, Zhiyuan
    JOURNAL OF CONTROLLED RELEASE, 2021, 336 : 262 - 273
  • [32] LTX-315, an oncolytic peptide converts "cold" tumors to "hot" in a majority of patients with advanced cancer: results from an ongoing phase I study
    Marabelle, Aurelien
    Baurain, Jean-Francois
    Awada, Ahmad
    Kristeleit, Rebecca
    Jossang, Dag-Erik
    Jebsen, Nina-Louise
    Loirat, Delphine
    Saunders, Andrew
    Olsen, Wenche
    Nicolaisen, Berit
    Sveinbjornsson, Baldur
    Gjerstad, Vibeke Sundvold
    Rekdal, Oystein
    Brunsvig, Pal
    Galon, Jerome
    Hermitte, Fabienne
    Gjertsen, Bjorn-Tore
    Armstrong, Anna
    Spicer, James
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [33] Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis
    Tang, Tianyu
    Huang, Xing
    Zhang, Gang
    Lu, Minghao
    Hong, Zhengtao
    Wang, Meng
    Huang, Junming
    Zhi, Xiao
    Liang, Tingbo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
  • [34] A Phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma
    Marabelle, Aurelien
    Baurain, Jean-Francois
    Awada, Ahmad
    Kristeleit, Rebbecca S.
    Loirat, Delphine
    Jossang, Dag E.
    Jebsen, Nina L.
    Sveinbjornsson, Baldur
    Rekdal, Oystein
    Gjerstad, Vibeke S.
    Brunsvig, Paal
    Galon, Jerome
    Hermitte, Fabienne
    Patel, Hamina
    Spicer, James
    CANCER RESEARCH, 2019, 79 (13)
  • [35] LTX-315, an oncolytic peptide, to convert immunogenically 'cold' tumors to 'hot' in patients with advanced or metastatic tumours: Results from an ongoing phase I study.
    Spicer, James F.
    Baurain, Jean -Francois
    Awada, Ahmad
    Kristeleit, Rebecca Sophie
    Jossang, Dag Erik
    Marabelle, Aurelien
    Loirat, Delphine
    Wold, Hedda
    Nicolaisen, Berit
    Rekdal, Oystein
    Olsen, Wenche Marie
    Saunders, Andrew
    Brunsvig, Paal
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Biophysical Characterization of LTX-315 Anticancer Peptide Interactions with Model Membrane Platforms: Effect of Membrane Surface Charge
    Koo, Dong Jun
    Sut, Tun Naw
    Tan, Sue Woon
    Yoon, Bo Kyeong
    Jackman, Joshua A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [37] Cell cycle progression data on human skin cancer cells with anticancer synthetic peptide LTX-315 treatment
    Santa-Gonzalez, Gloria A.
    Patino-Gonzalez, Edwin
    Manrique-Moreno, Marcela
    DATA IN BRIEF, 2020, 30
  • [38] Intratumoural treatment with LTX-315, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours
    Spicer, J.
    Awada, A.
    Brunsvig, P.
    Saunders, A.
    Olsen, W. M.
    Nicolaisen, B.
    Rekdal, O.
    Laruelle, M.
    Marjuadi, F.
    Vakili, J.
    Aftimos, P.
    Barthelemy, P.
    Deva, S.
    Baurain, J. F.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S113 - S113
  • [39] LTX-315, an oncolytic peptide, increases anticancer immunity mediated by CTLA4 blockade in an interleukin-2 receptor beta-chain dependent manner
    Yamazaki, Takahiro
    Vetizou, Marie
    Flores, Camila
    Marabelle, Aurelien
    Sveinbjornsson, Baldur
    Rekdal, Oystein
    Kroemer, Guido
    Zitvogel, Laurence
    CANCER RESEARCH, 2016, 76
  • [40] A novel immunotherapeutic treatment for experimental hepatocellular carcinoma (HCC) using the host-defense derived peptide LTX-315
    Line, Pal Dag
    Shi, Jihua
    Nestvold, Janne M.
    Wang, Meng Yu
    Kvalheim, Gunnar
    Rekdal, Oystein
    HEPATOLOGY, 2013, 58 : 332A - 332A
12345